GlassScriptPhysician profile
Alexandra Etkin
NPI 1932274156
$9,625.87
in general payments reported to CMS, 2019-2025
34 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $1,322 · 2021: $1,301 · 2022: $2,141 · 2023: $1,746 · 2024: $1,544 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.97 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,941.72 | 2019-2025 | |
| Lilly USA, LLC | $1,267.14 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $759.28 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $563.01 | 2019-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $473.48 | 2020-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.76 | 2019-2022 | |
| Pfizer INC. | $214.29 | 2021-2025 | |
| Amarin Pharma, INC. | $184.44 | 2019-2023 | |
| Vivus LLC | $158.29 | 2021-2025 | Pancreaze |
| Astellas Pharma US INC | $151.96 | 2023-2024 | Veozah, Myrbetriq |
| Amgen INC. | $138.34 | 2020-2025 | Evenity, Prolia, Repatha |
| Horizon Therapeutics Plc | $126.97 | 2021-2022 | |
| Allergan, INC. | $117.73 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $110.80 | 2020-2023 | Linzess |
| Arbor Pharmaceuticals, INC. | $108.89 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.42 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $98.92 | 2019-2022 | |
| Exact Sciences Corporation | $89.36 | 2023-2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $85.38 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $83.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $62.25 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $60.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.00 | 2019-2020 | |
| Antares Pharma, INC. | $38.32 | 2022-2023 | Tlando, Nocdurna, Xyosted |
| Medicomp INC | $37.46 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.00 | 2022 | |
| Scilex Pharmaceuticals INC. | $25.00 | 2021 | |
| Shield Therapeutics INC | $24.86 | 2025 | |
| Ardelyx, INC. | $23.33 | 2024 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $22.12 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.43 | 2021 | |
| Aimmune Therapeutics, INC. | $19.75 | 2024 | |
| Sunovion Pharmaceuticals INC. | $17.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Etkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.